T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08
The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pathways for treatment intensification.
